• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24040 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2019     National Institute for Health and Care Excellence (NICE) UrgoStart for treating diabetic foot ulcers and leg ulcers. NICE medical technologies guidance 42
2009     National Institute for Health and Care Excellence (NICE) Pemetrexed for the first-line treatment of non-small-cell lung cancer. NICE technology appraisal guidance 181
2025     National Institute for Health and Care Excellence (NICE) Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 1043
2021     National Institute for Health and Care Excellence (NICE) Metreleptin for treating lipodystrophy. NICE highly specialised technologies guidance 14
2018     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 543
2022     National Institute for Health and Care Excellence (NICE) Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 823
2016     National Institute for Health and Care Excellence (NICE) Radiation therapy for early Dupuytren's disease. NICE interventional procedures guidance 573
2007     National Institute for Health and Care Excellence (NICE) Laparoscopic nephrolithotomy and pyelolithotomy. NICE interventional procedures guidance 212
2022     National Institute for Health and Care Excellence (NICE) Memokath 051 Ureter stent for ureteric obstruction. NICE medical technologies guidance 75
2009     National Institute for Health and Care Excellence (NICE) Alitretinoin for the treatment of severe chronic hand eczema. NICE technology appraisal guidance 177
2025     National Institute for Health and Care Excellence (NICE) Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over. NICE technology appraisal guidance 1044
2020     National Institute for Health and Care Excellence (NICE) Volanesorsen for treating familial chylomicronaemia syndrome. NICE highly specialised technologies guidance 13
2018     National Institute for Health and Care Excellence (NICE) Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 544
2022     National Institute for Health and Care Excellence (NICE) Dexamethasone intravitreal implant for treating diabetic macular oedema. NICE technology appraisal guidance 824
2016     National Institute for Health and Care Excellence (NICE) Epiduroscopic lumbar discectomy through the sacral hiatus for sciatica. NICE interventional procedures guidance 570
2007     National Institute for Health and Care Excellence (NICE) Microwave ablation of hepatocellular carcinoma. NICE interventional procedures guidance 214
2022     National Institute for Health and Care Excellence (NICE) Optilume for treating recurrent bulbar urethral strictures. NICE medical technologies guidance 73
2009     National Institute for Health and Care Excellence (NICE) Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. NICE technology appraisal guidance 178
2025     National Institute for Health and Care Excellence (NICE) Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1041
2019     National Institute for Health and Care Excellence (NICE) Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2. NICE highly specialised technologies guidance 12
2018     National Institute for Health and Care Excellence (NICE) Gemtuzumab ozogamicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 545
2022     National Institute for Health and Care Excellence (NICE) Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis. NICE technology appraisal guidance 825
2016     National Institute for Health and Care Excellence (NICE) Endoscopic transluminal pancreatic necrosectomy. NICE interventional procedures guidance 567
2007     National Institute for Health and Care Excellence (NICE) Radiofrequency-assisted liver resection. NICE interventional procedures guidance 211
2022     National Institute for Health and Care Excellence (NICE) GreenLight XPS for treating benign prostatic hyperplasia. NICE medical technologies guidance 74
2009     National Institute for Health and Care Excellence (NICE) Tenofovir disoproxil for the treatment of chronic hepatitis B. NICE technology appraisal guidance 173
2025     National Institute for Health and Care Excellence (NICE) Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1042
2019     National Institute for Health and Care Excellence (NICE) Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations. NICE highly specialised technologies guidance 11
2018     National Institute for Health and Care Excellence (NICE) Padeliporfin for untreated localised prostate cancer. NICE technology appraisal guidance 546
2022     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal). NICE technology appraisal guidance 826
2016     National Institute for Health and Care Excellence (NICE) Percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture. NICE interventional procedures guidance 568
2007     National Institute for Health and Care Excellence (NICE) Laparoscopic insertion of peritoneal dialysis catheter. NICE interventional procedures guidance 208
2022     National Institute for Health and Care Excellence (NICE) Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer. NICE medical technologies guidance 72
2009     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of chronic lymphocytic leukaemia. NICE technology appraisal guidance 174
2025     National Institute for Health and Care Excellence (NICE) Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over. NICE technology appraisal guidance 1033
2019     National Institute for Health and Care Excellence (NICE) Patisiran for treating hereditary transthyretin amyloidosis. NICE highly specialised technologies guidance 10
2018     National Institute for Health and Care Excellence (NICE) Tofacitinib for moderately to severely active ulcerative colitis. NICE technology appraisal guidance 547
2022     National Institute for Health and Care Excellence (NICE) Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy. NICE technology appraisal guidance 827
2016     National Institute for Health and Care Excellence (NICE) Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. NICE interventional procedures guidance 569
2007     National Institute for Health and Care Excellence (NICE) Implantation of accommodating intraocular lenses for cataract. NICE interventional procedures guidance 209
2018     National Institute for Health and Care Excellence (NICE) Neuropad for detecting preclinical diabetic peripheral neuropathy. NICE medical technologies guidance 38
2009     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. NICE technology appraisal guidance 170
2025     National Institute for Health and Care Excellence (NICE) Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1038
2019     National Institute for Health and Care Excellence (NICE) Inotersen for treating hereditary transthyretin amyloidosis. NICE highly specialised technologies guidance 9
2018     National Institute for Health and Care Excellence (NICE) Decitabine for untreated acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 548
2022     National Institute for Health and Care Excellence (NICE) Ozanimod for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 828
2016     National Institute for Health and Care Excellence (NICE) Single-incision short sling mesh insertion for stress urinary incontinence in women. NICE interventional procedures guidance 566
2007     National Institute for Health and Care Excellence (NICE) Injectable bulking agents for faecal incontinence. NICE interventional procedures guidance 210
2022     National Institute for Health and Care Excellence (NICE) Faecal microbiota transplant for recurrent Clostridioides difficile infection. NICE medical technologies guidance 71
2009     National Institute for Health and Care Excellence (NICE) Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. NICE technology appraisal guidance 169
2025     National Institute for Health and Care Excellence (NICE) Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1039
2018     National Institute for Health and Care Excellence (NICE) Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency. NICE highly specialised technologies guidance 7
2018     National Institute for Health and Care Excellence (NICE) Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal). NICE technology appraisal guidance 549
2022     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 829
2016     National Institute for Health and Care Excellence (NICE) Miniature lens system implantation for advanced age-related macular degeneration. NICE interventional procedures guidance 565
2007     National Institute for Health and Care Excellence (NICE) Laparoscopic distal pancreatectomy. NICE interventional procedures guidance 204
2018     National Institute for Health and Care Excellence (NICE) iFuse for treating chronic sacroiliac joint pain. NICE medical technologies guidance 39
2009     National Institute for Health and Care Excellence (NICE) Amantadine, oseltamivir and zanamivir for the treatment of influenza. NICE technology appraisal guidance 168
2025     National Institute for Health and Care Excellence (NICE) Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy. NICE technology appraisal guidance 1040
2017     National Institute for Health and Care Excellence (NICE) Eliglustat for treating type 1 Gaucher disease. NICE highly specialised technologies guidance 5
2018     National Institute for Health and Care Excellence (NICE) Vandetanib for treating medullary thyroid cancer. NICE technology appraisal guidance 550
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of renal cell carcinoma. NICE technology appraisal guidance 830
2016     National Institute for Health and Care Excellence (NICE) Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation. NICE interventional procedures guidance 563
2007     National Institute for Health and Care Excellence (NICE) Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction. NICE interventional procedures guidance 205
2017     National Institute for Health and Care Excellence (NICE) SecurAcath for securing percutaneous catheters. NICE medical technologies guidance 34
2009     National Institute for Health and Care Excellence (NICE) Machine perfusion systems and cold static storage of kidneys from deceased donors. NICE technology appraisal guidance 165
2025     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1037
2017     National Institute for Health and Care Excellence (NICE) Migalastat for treating Fabry disease. NICE highly specialised technologies guidance 4
2018     National Institute for Health and Care Excellence (NICE) Lenvatinib for untreated advanced hepatocellular carcinoma. NICE technology appraisal guidance 551
2022     National Institute for Health and Care Excellence (NICE) Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 832
2016     National Institute for Health and Care Excellence (NICE) Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects. NICE interventional procedures guidance 560
2007     National Institute for Health and Care Excellence (NICE) Palliative photodynamic therapy for advanced oesophageal cancer. NICE interventional procedures guidance 206
2012     National Institute for Health and Care Excellence (NICE) PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites. NICE medical technologies guidance 9
2008     National Institute for Health and Care Excellence (NICE) Infliximab for acute exacerbations of ulcerative colitis. NICE technology appraisal guidance 163
2025     National Institute for Health and Care Excellence (NICE) Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment. NICE technology appraisal guidance 1036
2015     National Institute for Health and Care Excellence (NICE) Eculizumab for treating atypical haemolytic uraemic syndrome. NICE highly specialised technologies guidance 1
2018     National Institute for Health and Care Excellence (NICE) Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 552
2022     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating Waldenstrom's macroglobulinaemia. NICE technology appraisal guidance 833
2016     National Institute for Health and Care Excellence (NICE) Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting. NICE interventional procedures guidance 561
2006     National Institute for Health and Care Excellence (NICE) Intrauterine laser ablation of placental vessels for the treatment of twin-to-twin transfusion syndrome. NICE interventional procedures guidance 198
2011     National Institute for Health and Care Excellence (NICE) MiraQ for assessing graft flow during coronary artery bypass graft surgery. NICE medical technologies guidance 8
2008     National Institute for Health and Care Excellence (NICE) Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin. NICE technology appraisal guidance 159
2025     National Institute for Health and Care Excellence (NICE) Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention. NICE interventional procedures guidance 802
2018     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE technology appraisal guidance 554
2022     National Institute for Health and Care Excellence (NICE) SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal). NICE technology appraisal guidance 834
2016     National Institute for Health and Care Excellence (NICE) Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules. NICE interventional procedures guidance 562
2006     National Institute for Health and Care Excellence (NICE) Septostomy with or without amnioreduction for the treatment of twin-to-twin transfusion syndrome. NICE interventional procedures guidance 199
2018     National Institute for Health and Care Excellence (NICE) Peristeen Plus transanal irrigation system for managing bowel dysfunction. NICE medical technologies guidance 36
2008     National Institute for Health and Care Excellence (NICE) Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. NICE technology appraisal guidance 157
2019     National Institute for Health and Care Excellence (NICE) Regorafenib for previously treated advanced hepatocellular carcinoma. NICE technology appraisal guidance 555
2022     National Institute for Health and Care Excellence (NICE) Fostamatinib for treating refractory chronic immune thrombocytopenia. NICE technology appraisal guidance 835
2016     National Institute for Health and Care Excellence (NICE) Endovenous mechanochemical ablation for varicose veins. NICE interventional procedures guidance 557
2006     National Institute for Health and Care Excellence (NICE) Photodynamic therapy for early-stage oesophageal cancer. NICE interventional procedures guidance 200
2018     National Institute for Health and Care Excellence (NICE) Thopaz+ portable digital system for managing chest drains. NICE medical technologies guidance 37
2008     National Institute for Health and Care Excellence (NICE) Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza. NICE technology appraisal guidance 158
2019     National Institute for Health and Care Excellence (NICE) Darvadstrocel for treating complex perianal fistulas in Crohn's disease. NICE technology appraisal guidance 556
2022     National Institute for Health and Care Excellence (NICE) Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 836
2016     National Institute for Health and Care Excellence (NICE) Microwave ablation for treating liver metastases. NICE interventional procedures guidance 553
2006     National Institute for Health and Care Excellence (NICE) Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. NICE interventional procedures guidance 202
2022     National Institute for Health and Care Excellence (NICE) Sleepio to treat insomnia and insomnia symptoms. NICE medical technologies guidance 70